Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03075423
Title Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (SUNIFORECAST)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nicola Goekbuget
Indications

renal cell carcinoma

Therapies

Sunitinib

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.